


Standardization of Medicinal Plants: Ensuring Quality, Safety, and Global Regulatory Compliance in Herbal Drug Development

Azza Dawoud H. Dawoud^{1,2} , Mohammed abdalbagi² 

¹Medicinal and Aromatic Plants & Traditional Medicine Research Institute, National Center of Research, Sudan.

²Pharmaceutical Department, Faculty of Pharmacy, National Ribat University

Article Info	ABSTRACT
Article type: Review Article	Objective: Medicinal plants have long played a pivotal role in traditional and modern healthcare systems due to their therapeutic potential. However, significant variability in their chemical composition presents challenges for ensuring safety, efficacy, and quality in herbal pharmaceutical products. This review aims to emphasize the critical role of standardization in the pharmaceutical development of medicinal plants.
Article History: Received: 20 March 2025 Revised: 22 May 2025 Accepted: 01 Dec 2025 Published Online: 20 Sep 2025	Methodology: The methodology includes a comprehensive analysis of literature and regulatory documents to identify current practices, standardization techniques, and global frameworks. Results: Key findings highlight the importance of standardization across the entire lifecycle of herbal medicines from cultivation and harvesting to extraction, analysis, and final formulation. Various methods such as botanical authentication, physicochemical testing, chromatographic and spectroscopic analysis, DNA barcoding, and biological assays are discussed. Additionally, the review outlines major challenges including phytochemical complexity, variability in raw materials, regulatory disparities, and limited access to advanced technologies in developing regions. It also discusses the need for harmonized global standards and integration of modern scientific tools like genomics and chemometrics.
 Correspondence to: Azza Dawoud H. Dawoud	Conclusion: This review also outlines future directions for research and regulatory integration aimed at enhancing the consistency, safety, and global acceptance of herbal medicines. The major contribution of this paper is its comprehensive synthesis of standardization strategies, challenges, and regulatory considerations, offering a roadmap to bridge the gap between traditional herbal practices and modern pharmaceutical standards.
Email: azzadawoudhussien@gmail.com	Keywords: <i>Phytotherapy, Phytochemical Analysis, Quality Control, Herbal Medicine, Standardization</i>
➤ How to cite this paper Dawoud H. Dawoud A, abdalbagi M. Standardization of Medicinal Plants: Ensuring Quality, Safety, and Global Regulatory Compliance in Herbal Drug Development. <i>Plant Biotechnology Persa</i> . 2025; 7(4): 89-102.	

Introduction

Medicinal plants have long constituted a cornerstone of healthcare systems across diverse cultures, significantly contributing to the development of numerous modern pharmaceutical agents [1]. They remain a vital source of bioactive compounds, particularly in developing countries, where up to 80% of the population still depends on traditional medicine as a primary means of healthcare [2].

In recent decades, the global demand for plant-based medicines has surged, driven by the growing interest in natural therapies, the rise of lifestyle-related chronic

diseases, and the increasing awareness of adverse effects associated with synthetic drugs [3].

Despite their widespread use and therapeutic potential, herbal medicines face numerous challenges in pharmaceutical development, particularly regarding consistency, safety, efficacy, and regulatory acceptance. The chemical complexity and natural variability of plant materials present significant obstacles to quality control, and the absence of standardization often results in

inconsistent clinical outcomes, reduced patient trust, and safety concerns [4,5].

Standardization involves the implementation of well-defined and validated procedures to ensure consistency in the identity, purity, concentration of active constituents, and overall quality of herbal products across different batches. This process is essential for the development of safe, effective, and reproducible phytomedicines, serving as a critical link between traditional practices and contemporary pharmaceutical standards [6,7]. Through standardization, medicinal plant materials are comprehensively characterized not only by their botanical and phytochemical attributes but also by their biological activities and therapeutic efficacy.

Furthermore, standardized herbal preparations are better positioned to comply with the regulatory requirements of international bodies such as the World Health Organization (WHO), the European Medicines Agency (EMA), and the U.S. Food and Drug Administration (FDA), all of which increasingly demand robust scientific evidence regarding the quality, safety, and efficacy of herbal products [8]. In addition, standardization facilitates international trade by ensuring that herbal formulations adhere to consistent quality specifications across global markets.

In this review, we will first define standardization, followed by a discussion of its methodologies, challenges, importance in pharmaceutical contexts, and future directions.

What is Standardization of Medicinal Plants?

Standardization of medicinal plants is the process of ensuring the consistent quality, efficacy, and safety of herbal materials and formulations by applying specific scientific and technical methods. It aims to minimize variability in the chemical composition and therapeutic properties of plant-based products that naturally occur due to environmental, genetic, and processing factors (4).

Unlike synthetic drugs that are characterized by a single active molecule, medicinal plants often contain a complex mixture of phytochemicals, many of which contribute synergistically to their therapeutic effects. This complexity necessitates a holistic approach to quality control that goes beyond identifying a single marker compound. Standardization, therefore, involves a comprehensive evaluation of the herbal raw materials and finished products to ensure their identity, purity, chemical profile, and biological activity [6].

For instance, standardized extracts of *Ginkgo biloba* are required to contain defined amounts of flavonoids and terpene lactones to ensure consistent cognitive-enhancing effects. Similarly, *Curcuma longa* (turmeric) preparations are standardized based on curcumin content, the key bioactive compound responsible for its anti-inflammatory properties.

Methodology

This review was conducted using a structured literature review approach, following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines to ensure transparency, reproducibility, and scientific rigor [9].

Databases and Search Strategy

A comprehensive literature search was conducted in four major databases: PubMed, Scopus, Web of Science, and Google Scholar. These databases were selected due to their extensive coverage of biomedical, pharmaceutical, and interdisciplinary scientific literature [10,11]. The search included articles published between 2000 and 2024 and was restricted to publications in English. Search terms included combinations of Medical Subject Headings (MeSH) and Boolean operators, such as: ("medicinal plants" OR "herbal medicine") AND ("standardization" OR "quality control" OR "phytochemical analysis" OR "regulatory guidelines") AND ("chromatography" OR "DNA barcoding" OR "pharmacognosy")

Inclusion Criteria

Peer-reviewed original research or review articles. Articles addressing standardization techniques, quality control, phytochemical analysis, or regulatory considerations in herbal medicine. Studies that describe analytical, botanical, molecular, or biological methods of standardization.

Exclusion Criteria

Non-peer-reviewed content such as opinion pieces, news articles, or conference abstracts. Articles not available in full text or written in languages other than English. Studies focusing solely on clinical efficacy without discussing standardization aspects.

Screening and Selection

A total of 312 articles were initially retrieved. After removal of duplicates (n = 42), 270 articles remained for

screening. Titles and abstracts were reviewed for relevance, resulting in the exclusion of 165 articles. The full texts of 105 articles were assessed for eligibility, and 37 were excluded due to methodological limitations or lack of relevance. Ultimately, 68 articles were included in this review.

Key Aspects of Standardization

Botanical Identification

Accurate taxonomic identification is the first and most crucial step in standardization. This involves evaluating both macroscopic and microscopic features of the plant to ensure the correct species is being used and to avoid misidentification or substitution.

Authentication

Authentication ensures that the plant material originates from a genuine source and confirms the absence of adulterants. This process may involve botanical verification, genetic analysis, and comparison with authenticated reference materials.

Phytochemical Profiling

This aspect includes the identification and characterization of major bioactive or marker compounds using chromatographic or spectroscopic methods such as HPLC or TLC. Profiling helps determine therapeutic potential and consistency across batches.

Quantification of Active Components

Measuring the concentration of active constituents is essential for determining dosage and efficacy. Standardization involves setting acceptable ranges for these components to ensure therapeutic reliability.

Physico-chemical Testing

This includes evaluating basic quality parameters like moisture content, ash value, extractive values, and pH levels. These tests provide insights into the purity and stability of the herbal material.

Biological Standardization

Biological assays, whether *in vitro* or *in vivo*, are used to confirm the therapeutic activity of the plant material. This helps correlate chemical composition with pharmacological effects and is especially important when active compounds are unknown or act synergistically.

The goal of standardization is not only to assure quality and reproducibility but also to build scientific credibility and regulatory acceptance for herbal medicines. It provides a basis for establishing dosage, efficacy, and safety standards that are critical for clinical application and pharmaceutical manufacturing [8].

Standardization Methods for Medicinal Plants

Standardization of medicinal plants employs a combination of analytical, botanical, physical, chemical, and biological techniques to ensure product quality, safety, and therapeutic consistency. These methods help determine the identity, purity, strength, and composition of both raw plant materials and finished herbal products [12, 13].

Botanical and Organoleptic Evaluation

This is the first step in standardization, involving:

Macroscopic analysis: color, odor, taste, size, shape, texture.

Microscopic analysis: identification of cellular structures and tissues through microscopic examination.

These methods help authenticate the plant and detect adulterants or substitutions [13].

Physicochemical Parameters

Physicochemical analysis forms a cornerstone in the initial evaluation of herbal raw materials, providing essential information about their identity, purity, and storage stability. One of the most critical parameters is moisture content, which directly influences microbial growth and degradation. Excessive moisture may lead to mold contamination, fermentation, or loss of active constituents during storage.

Ash values, including total ash and acid-insoluble ash, serve as indicators of the presence of inorganic residues and extraneous matter. High ash content can signify adulteration or improper processing techniques.

Extractive values, measured using solvents like alcohol and water, provide an estimate of the quantity of active or soluble phytochemicals. Variations in these values can reflect differences in raw material quality or extraction efficiency.

Additionally, the foreign matter test assesses the presence of extraneous substances such as soil, sand, insects, or other plant parts, which may compromise both quality and safety. Together, these tests establish the baseline quality

attributes necessary for further standardization and formulation [12].

Phytochemical Screening

Preliminary phytochemical screening serves as a foundational step in understanding the chemical makeup of medicinal plants. This process involves qualitative detection of key secondary metabolite classes such as alkaloids, flavonoids, terpenoids, glycosides, and tannins. These compounds are often responsible for the pharmacological activities of herbal drugs and may act individually or synergistically.

For example, the presence of alkaloids may indicate potential analgesic or antimalarial properties, while flavonoids are often linked to antioxidant and anti-inflammatory effects. Detecting these compounds early in the analysis helps prioritize which plants warrant further investigation using more advanced techniques like HPLC or NMR. Moreover, these initial tests can signal the need for specific extraction methods or stability considerations during product development [12].

Chromatographic and Spectroscopic Techniques

Chromatographic techniques are central to the standardization of herbal materials due to their ability to separate, identify, and quantify complex mixtures of phytochemicals. Thin Layer Chromatography (TLC) remains a widely used screening tool for generating chemical fingerprints that help in plant authentication and batch-to-batch comparison [12].

More advanced methods such as High-Performance Liquid Chromatography (HPLC) and High-Performance Thin Layer Chromatography (HPTLC) offer high precision and reproducibility in quantifying specific bioactive compounds. For example, curcumin in *Curcuma longa* or ginsenosides in *Panax ginseng* can be accurately measured using these platforms, ensuring therapeutic consistency [14-16].

Complementing chromatography, spectroscopic techniques such as UV-Vis, Infrared (IR), Nuclear Magnetic Resonance (NMR), and Mass Spectrometry (MS) provide structural and compositional insights. These methods are particularly valuable in fingerprint analysis and compound elucidation, playing a pivotal role in both quality control and regulatory submission [17,18].

DNA Barcoding

DNA barcoding has emerged as a powerful molecular tool for precise botanical identification, especially in cases

where traditional morphological methods fall short. It is particularly useful for processed or powdered herbal materials where visual identification is impossible [19-21]. This technique relies on standardized DNA regions, such as *rbcL* and *matK*, and is increasingly being incorporated into pharmacopoeial standards [22, 23].

Classification of Standardization Approaches

Standardization of medicinal plants can be broadly categorized into four interrelated but distinct domains: physicochemical, phytochemical (chemical), biological, and molecular standardization. Clarifying these categories is essential for understanding the specific tools, objectives, and regulatory expectations associated with each.

Physicochemical Standardization

This involves assessing basic physical and chemical parameters such as moisture content, pH, ash values, and extractive values. These tests are crucial for establishing raw material purity and ensuring consistency during processing and storage [13].

Phytochemical (Chemical) Standardization

This level focuses on the identification and quantification of specific active compounds or markers using techniques like HPLC, GC-MS, TLC, and UV-Vis spectroscopy. It ensures that the pharmacologically active constituents are present at defined concentrations across all batches [12].

Biological Standardization

Biological assays, both *in vitro* and *in vivo*, are used to verify the pharmacological activity of the herbal material. This step is especially important when the active constituents are unknown or work synergistically. Examples include anti-inflammatory or antioxidant activity tests using cell or animal models [35].

Molecular (Genetic) Standardization

Techniques such as DNA barcoding, qPCR, and genomic fingerprinting confirm the botanical identity of plant materials at the species or even cultivar level. These tools are particularly useful for detecting adulteration and ensuring the authenticity of powdered or processed plant products [20]. Integrating these four levels of standardization leads to a more robust, reproducible, and regulatory-compliant herbal product development process.

Comparative Table: Standardization Methods

Table 1: Comparison of Standardization Techniques for Medicinal Plants

Method	Accuracy	Cost	Complexity	Accessibility	Best Use Case
Macroscopic/Microscopic	Low-Medium	Low	Low	High	Preliminary authentication
HPLC	High	High	High	Medium (labs)	Quantification of markers
GC-MS	High	High	High	Low (specialized)	Volatile compounds
TLC	Medium	Low-Medium	Medium	High	Rapid fingerprinting
DNA Barcoding	Very High	Medium-High	Medium	Low (labs)	Species identification
UV-Vis Spectroscopy	Medium	Low	Low	High	Total content

Importance of Standardization in Pharmaceutical Manufacturing

Standardization is a cornerstone in the manufacturing of effective and safe herbal medicines. The intrinsic variability in the chemical composition of medicinal plants, influenced by factors such as geographical origin, harvesting season, and processing methods, underscores the need for stringent quality control measures [24,25].

Ensuring Consistency and Quality

Consistent therapeutic outcomes require herbal formulations to have uniform levels of bioactive constituents. Standardization ensures that each batch of product delivers predictable efficacy, thus enhancing consumer confidence and clinical reliability [14].

A notable example is the German company Schwabe Pharmaceuticals, which produces standardized extracts of

Ginkgo biloba (EGb 761®) with specified amounts of flavonoids and terpenoids, ensuring consistent effects in cognitive disorders. Similarly, Himalaya Drug Company in India standardizes herbal formulations like Liv.52®, using defined phytochemical markers to guarantee hepatoprotective activity.

Enhancing Safety Profiles

Herbal products may carry risks of contamination with heavy metals, pesticides, or microbial toxins. Standardization involves rigorous testing and quality assurance protocols to eliminate or minimize such risks, safeguarding public health [26].

Meeting Regulatory Requirements

To align with international pharmaceutical regulations, standardized herbal products must comply with Good Manufacturing Practices (GMP) and quality standards defined by bodies such as the European Medicines Agency

(EMA) and United States Pharmacopeia (USP) [27]. Standardization simplifies the regulatory approval process and supports market access.

Supporting Evidence-Based Medicine

Scientific validation of traditional herbal practices depends on reproducible data. Standardization enables reliable pharmacological and clinical studies, supporting the integration of phytomedicines into modern healthcare systems [28].

Enabling Industrial Innovation and Scale-Up

Without standardization, scaling up from traditional to industrial herbal formulations is nearly impossible. It facilitates industrial innovation, such as developing novel delivery systems, cosmeceuticals, and phytopharmaceuticals with guaranteed efficacy and safety [29].

In the absence of standardization, commercialization of herbal products faces major hurdles. Inconsistent product quality leads to variable clinical outcomes, loss of consumer trust, and difficulty in gaining regulatory approval. Additionally, international market access becomes limited, as many countries require documented evidence of quality, safety, and reproducibility. This can deter investment and hinder the development of large-scale production facilities.

Quantitative Impact of Standardization

Quantitative data from international organizations and market analyses highlight the tangible benefits of medicinal plant standardization. According to a 2022 WHO report, approximately 70% of herbal products rejected at international borders (e.g., EU, US) were due to quality control issues such as contamination, inconsistent active ingredient levels, or incorrect botanical identification [30].

Furthermore, countries with established herbal pharmacopoeias and enforcement mechanisms (e.g., Germany, China, India) account for over 65% of the global herbal drug market share, despite representing less than 35% of total medicinal plant biodiversity [31]. This indicates a direct correlation between regulatory standardization and market access.

A multicenter study published in *Journal of Herbal Pharmacology* in 2021 found that standardized herbal preparations reduced batch variability by up to 80%, and improved clinical outcome reproducibility in herbal

formulations for inflammatory and metabolic disorders [32].

Moreover, a review of pharmacovigilance reports from the EMA between 2010 and 2020 indicated that over 85% of adverse events linked to herbal medicines were associated with non-standardized products lacking proper labeling or authentication [33]. These findings emphasize that standardization not only improves marketability but also plays a crucial role in public health safety and clinical reliability.

Challenges in Standardizing Herbal Medicines

Despite the critical importance of standardization, there are several significant challenges that hinder the consistent production of high-quality herbal medicines:

Variability in Plant Material

Challenge: The chemical composition of medicinal plants varies due to genetic differences, geographic location, climate, soil conditions, harvest time, and post-harvest processing [34].

Potential Solution: Implement Good Agricultural and Collection Practices (GACP) to control growing conditions, alongside DNA barcoding to verify genetic consistency. Cultivation in controlled environments (e.g., greenhouses) can also minimize variability.

Complexity of Phytochemical Constituents

Challenge: Herbal medicines contain numerous bioactive compounds acting synergistically, making it difficult to identify and standardize key markers [13].

Potential Solution: Adopt chemometric approaches (e.g., PCA, metabolomics) to identify synergistic compound clusters. Focus on standardizing multi-marker profiles rather than single compounds.

Lack of Unified Global Standards

Challenge: Differences in regulatory requirements among countries complicate international trade [35].

Potential Solution: Advocate for harmonized guidelines through international collaborations (e.g., WHO-ICH partnerships) and adopt regionally adaptable frameworks that align with local traditions and global standards.

Technological and Resource Limitations

Challenge: Advanced techniques like HPLC or GC-MS may be inaccessible in developing countries [36].

Potential Solution: Promote low-cost alternatives (e.g., HPTLC, UV-Vis spectroscopy) and capacity-building initiatives (e.g., training programs, shared analytical facilities).

Contextual Barriers in Low- and Middle-Income Countries

In many low- and middle-income countries (LMICs), the adoption and implementation of medicinal plant standardization face multifaceted challenges beyond technical limitations. Cultural preferences for traditional, unprocessed remedies may resist standardization protocols perceived as “Westernized” or detached from local knowledge systems [5].

Economically, many small-scale producers and traditional healers lack the resources to comply with international quality standards due to the high costs of testing, certification, and regulatory procedures [22]. Infrastructural constraints—such as limited laboratory access, absence of national reference standards, and insufficient supply chains for quality raw materials—further exacerbate the problem [21].

Regulatory systems are often underdeveloped or fragmented, leading to inconsistent enforcement and a lack of trust between regulators and traditional medicine practitioners [26]. Moreover, the lack of coordination between health, agriculture, and trade ministries in some countries prevents the creation of integrated policies that support both standardization and economic empowerment of local producers [2].

Addressing these barriers requires tailored strategies that integrate cultural respect, affordable technologies, community participation, and sustained governmental commitment.

6.6 Real-World Case Studies in Herbal Standardization

Several case studies highlight the practical challenges and successes in implementing herbal standardization across different countries.

One widely cited success is Schwabe Pharmaceuticals in Germany, which standardizes Ginkgo biloba extracts (EGb 761®) to contain precisely 24% flavone glycosides and 6% terpene lactones. This standardization has enabled the product to meet strict EMA and WHO guidelines and gain international acceptance [8].

In India, the Ayurvedic Pharmacopoeia of India (API) has been instrumental in standardizing over 600 Ayurvedic herbs using chromatographic and physicochemical

techniques. Products like Liv.52® by Himalaya Herbal are standardized on multiple phytochemical markers and have seen global success [16].

In contrast, a 2016 pilot project in Nigeria aimed at introducing Good Manufacturing Practices (GMP) into herbal medicine production failed due to inadequate laboratory infrastructure, lack of skilled personnel, and absence of financial incentives. This highlighted how infrastructure and economic readiness critically affect standardization adoption [35].

Another example is China, where integration of modern technologies such as metabolomics and DNA barcoding into the Chinese Pharmacopoeia has led to international recognition of products like Tongrentang’s traditional herbal tablets [25].

These case studies underscore that while standardization can elevate the safety and quality of herbal products, its success depends heavily on institutional support, scientific infrastructure, and regulatory enforcement tailored to local contexts.

In addition to the previously mentioned examples, other notable cases further illustrate the spectrum of outcomes in herbal standardization practices:

In Thailand, the government-backed Thai Herbal Pharmacopoeia has standardized over 80 herbal products since 2012, supporting both local use and export. Successful examples include standardized extracts of *Andrographis paniculata* and *Centella asiatica*, which are now widely used in public hospitals [37].

Conversely, in Ghana, a 2018 effort to introduce mandatory standardization protocols for traditional herbal clinics faced resistance due to limited laboratory capacity, lack of incentives for compliance, and fears among healers of knowledge appropriation. This led to partial adoption and highlighted the importance of trust-building and community involvement [38].

A commercial failure case is seen with a Nigerian herbal company that launched a phytomedicine for diabetes based on *Vernonia amygdalina*, but inconsistent active compound levels across batches led to market withdrawal after complaints of variable efficacy [39].

On the other hand, Morocco has successfully developed a national essential oils standard, supported by the Moroccan Institute for Standardization (IMANOR), which has improved export potential for *Artemisia herba-alba*

and *Rosmarinus officinalis* oils—particularly toward the EU market [40].

These examples reaffirm that standardization is not only a scientific or regulatory process but also a sociopolitical and economic endeavor requiring stakeholder alignment and system-wide coordination.

Economic and Market Constraints

Economic and market factors play a pivotal role in the adoption and sustainability of medicinal plant standardization, particularly in resource-limited settings. The implementation of Good Manufacturing Practices (GMP), analytical testing (e.g., HPLC, DNA barcoding), and compliance with international standards entails significant financial investments, which are often beyond the capacity of small-scale producers and cooperatives [21].

For instance, the establishment of a basic herbal testing laboratory with HPLC, UV-Vis spectrophotometer, and microbial testing equipment can cost upwards of \$120,000 to \$200,000 USD [41]. Annual operational costs, including reagents, calibration, and personnel salaries, may exceed \$30,000 USD, representing a substantial burden in countries with fragile health and research systems.

In many developing countries, the cost of setting up national reference laboratories or complying with ISO/WHO guidelines is exacerbated by poor infrastructure, limited access to foreign currency, and fluctuating regulatory frameworks. Moreover, the lack of government subsidies or tax incentives discourages private investment in quality assurance infrastructure [35].

From a market perspective, standardized herbal products often face challenges such as limited market access, fluctuating export regulations, and competition with synthetic drugs and non-standardized traditional products. International markets increasingly demand documentation of safety, efficacy, and reproducibility, which local producers may be unable to provide due to the absence of certification or traceability systems [26].

Additionally, the economic viability of herbal standardization is influenced by market size, consumer awareness, and the profitability of specific plants. For example, high-value species like *Panax ginseng* or *Ginkgo biloba* attract investment, whereas low-market-volume plants may remain neglected despite their therapeutic potential [12].

Addressing these challenges requires integrated policies that provide financial support, build infrastructure,

promote public-private partnerships, and strengthen regional markets for standardized phytomedicines.

Training and Capacity Building Deficiencies

A persistent challenge in the standardization of medicinal plants, especially in developing countries, is the shortage of trained personnel and institutional capacity. The lack of expertise in pharmacognosy, phytochemistry, molecular biology, and quality control techniques severely hampers the ability to conduct proper standardization at both laboratory and industrial scales [22].

Many universities in low- and middle-income countries lack dedicated programs for herbal standardization or hands-on training modules for modern analytical tools such as HPLC, DNA barcoding, or spectroscopic fingerprinting. This skills gap results in a dependency on international partners or outsourcing, which is often unsustainable and expensive [21].

Furthermore, national drug regulatory authorities in these regions often operate with limited staff and resources, making it difficult to enforce quality standards or evaluate dossiers for herbal products.

Efforts to build capacity have been initiated by international bodies. For example, the WHO's Training of Trainers (ToT) programs and the Traditional Medicine Strategy (2014–2023) emphasize institutional development and cross-country collaboration [2]. However, scaling these initiatives and tailoring them to country-specific needs remains a major task.

Strengthening human resources through continuous professional education, academic-industry partnerships, and investment in postgraduate training programs is crucial to achieving sustainable and context-appropriate standardization of herbal medicines.

Socioeconomic Barriers in Low-Income Countries

The implementation of medicinal plant standardization in low-income countries is frequently hindered by a complex interplay of economic hardship, social constraints, and governance challenges. Unlike industrialized nations, many resource-limited settings suffer from fragile health systems, poor infrastructure, and inadequate investment in research and quality control.

Poverty and limited health budgets often force governments to prioritize immediate healthcare needs over long-term investments in herbal standardization

infrastructure. As a result, basic tools such as certified laboratories, quality control equipment, and trained personnel are often unavailable or centralized in capital cities, making them inaccessible to rural producers [21].

On the social front, lack of awareness about the importance of standardization among traditional healers and local communities creates resistance to adopting quality control practices. In some cases, herbalists may fear that documentation or regulation will lead to loss of proprietary knowledge or external exploitation [8].

Gender disparities also influence access to training and participation in standardization projects, as women—who make up a large portion of the informal herbal sector in Africa and South Asia—are often excluded from formal capacity-building programs [41].

Moreover, the absence of clear national policies linking traditional medicine to public health systems leaves a regulatory vacuum that discourages innovation and investment. To overcome these barriers, a multisectoral approach is required—one that combines health policy, education, rural development, and equitable access to scientific tools.

Methods and Techniques for Standardization of Medicinal Plants

Several advanced analytical and biotechnological approaches have been developed and refined to support the standardization of medicinal plants and their derived products. These methodologies are essential for the accurate identification, quantification, and quality assurance of bioactive constituents.

Macroscopic and Microscopic Evaluation

The preliminary identification of raw plant materials involves macroscopic (visual) and microscopic assessments, which are critical for detecting adulterants and verifying botanical authenticity [42].

Physicochemical Analysis

Key physicochemical parameters—such as moisture content, ash values, extractive values, and the presence of foreign matter—are evaluated to determine the quality, purity, and overall integrity of plant materials [43].

Chromatographic Techniques

Chromatographic methods including High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC),

Thin Layer Chromatography (TLC), and Ultra-Performance Liquid Chromatography (UPLC) are widely employed to separate, identify, and quantify active constituents with high precision, sensitivity, and specificity [27].

Spectroscopic Methods

Spectroscopic techniques such as Ultraviolet-Visible (UV-Vis) spectroscopy, Infrared (IR) spectroscopy, Nuclear Magnetic Resonance (NMR), and Mass Spectrometry (MS) offer detailed structural and qualitative information on phytochemicals and are instrumental in generating fingerprint profiles of herbal extracts [18].

DNA Barcoding and Molecular Techniques

Genetic methods like DNA barcoding provide precise species-level identification, helping to prevent substitution and adulteration in raw herbal materials [20].

Bioassays and Pharmacological Testing

Biological assays and pharmacological testing confirm the activity and potency of herbal extracts, complementing chemical standardization by correlating chemical profiles with biological effects [44].

Emerging Technologies in Herbal Standardization

Recent advancements in analytical and computational technologies have opened new frontiers in the standardization of medicinal plants. These tools enhance the precision, reproducibility, and scalability of herbal drug development, particularly in the face of complex phytochemical matrices.

Genomics and transcriptomics enable the identification of species-specific genetic markers and gene expression profiles related to bioactive compound production. These tools are especially useful in plant authentication, chemotype differentiation, and in tracing the genetic basis for phytochemical variability [25].

Chemometric approaches, such as Principal Component Analysis (PCA), Partial Least Squares (PLS), and metabolomics, are increasingly employed to analyze high-dimensional phytochemical data. These techniques allow the identification of compound clusters that work synergistically, moving standardization beyond single-marker models [15].

Artificial Intelligence (AI) and machine learning algorithms are emerging as powerful tools for predictive modeling of

herbal efficacy, spectral data interpretation, and real-time quality assessment during production [45].

Additionally, nanosensors and portable devices (e.g., paper-based colorimetric assays) offer low-cost, field-applicable alternatives for rapid detection of phytoconstituents or contaminants. These tools are particularly valuable in low-resource settings where access to advanced laboratories is limited [46].

Integrating these technologies into regulatory frameworks and pharmacopoeial standards will be crucial to achieving high-precision, cost-effective, and globally accepted herbal standardization protocols.

Advanced Analytical Frontiers: AI and Nanotechnology in Herbal Standardization

Emerging technologies such as Artificial Intelligence (AI) and nanotechnology are revolutionizing the field of herbal standardization by enabling faster, more precise, and cost-effective analytical approaches.

In quality control, AI-powered algorithms are being trained to interpret complex chromatographic and spectroscopic datasets with greater speed and accuracy than traditional manual methods. For instance, machine learning models can detect adulteration patterns, classify plant species, or predict the concentrations of active constituents using data from HPLC, FTIR, or NMR [45]. These systems reduce human bias and are particularly useful in high-throughput industrial settings.

Meanwhile, nanosensors miniaturized devices capable of detecting molecular targets in minute quantities are gaining popularity for their portability and sensitivity. Applications include detecting heavy metal contamination, identifying phytochemical markers, and even monitoring the freshness or degradation of herbal raw materials in real time. Paper-based nanosensors and colorimetric strips, for example, offer low-cost solutions suitable for field-level quality assessments in low-resource regions [46].

Together, these tools represent a paradigm shift from conventional bench-top testing to smart, real-time, and decentralized quality assurance systems, paving the way for more inclusive and accessible standardization practices globally.

Importance of Standardization for Safety and Efficacy

Standardization is fundamental to ensuring both the safety and efficacy of herbal medicines. Without standardized

methods, the therapeutic outcomes may vary, and safety risks may arise.

Ensuring Consistent Therapeutic Effect

Standardization guarantees that every batch of herbal medicine contains a consistent number of active compounds, which directly influences the reproducibility of therapeutic effects [12].

Minimizing Adverse Effects and Toxicity

Proper standardization includes testing for contaminants such as heavy metals, pesticides, microbial load, and toxins, thus reducing the risk of adverse reactions [47].

Facilitating Regulatory Approval and Market Access

Standardized herbal products meet regulatory requirements, which facilitate their acceptance in global markets, ensuring consumer trust and product legitimacy [3].

Enhancing Research and Development

Standardization provides a reliable foundation for clinical trials and pharmacological studies, accelerating the discovery and development of new phytopharmaceuticals [48].

Safety Concerns, Toxicity Testing, and Drug-Herb Interactions

While medicinal plants are often perceived as inherently safe due to their natural origin, numerous studies have demonstrated that unstandardized or improperly used herbal products can cause serious adverse effects, including organ toxicity, allergic reactions, and interactions with conventional drugs [3].

Toxicity testing is an essential component of herbal standardization. Standardized extracts should undergo acute, sub-chronic, and chronic toxicity evaluations, preferably using internationally recognized protocols such as those outlined by OECD or WHO. These tests assess potential hepatotoxicity, nephrotoxicity, genotoxicity, and reproductive toxicity. In some cases, traditional formulations have been shown to contain unsafe levels of heavy metals or pesticide residues, particularly in products sold through informal markets [23].

Drug-herb interactions are another growing concern, especially in patients using multiple medications. For

instance, St. John's Wort has been documented to reduce the efficacy of antiretrovirals, anticoagulants, and immunosuppressants by inducing cytochrome P450 enzymes [49]. Without proper labeling or guidance, such interactions may go unnoticed, resulting in reduced therapeutic outcomes or enhanced toxicity.

To improve post-market surveillance, pharmacovigilance systems tailored to herbal medicines must be strengthened. This includes encouraging healthcare professionals and patients to report adverse events, maintaining herbal safety databases, and requiring manufacturers to include warning labels and contraindication information on packaging.

Ultimately, integrating safety assessment into the standardization process ensures not only product quality and efficacy but also consumer protection and public trust.

Regulatory Frameworks for Standardization of Medicinal Plants

The regulation of herbal medicines varies worldwide, but all frameworks emphasize the importance of quality, safety, and efficacy through standardization.

International Guidelines

The World Health Organization (WHO) provides global guidelines for the quality control and standardization of herbal medicines, encouraging member states to adopt these standards to ensure product safety and efficacy [13].

Regional and National Regulations

European Union (EU): The EU regulates herbal medicinal products under the Traditional Herbal Medicinal Products Directive (THMPD), requiring evidence of quality, safety, and traditional use [50].

United States (USA): The Food and Drug Administration (FDA) oversees dietary supplements under the Dietary Supplement Health and Education Act (DSHEA), emphasizing good manufacturing practices (GMP) for quality assurance [51].

China: The Chinese Pharmacopoeia includes stringent quality standards and monographs for traditional Chinese medicines, integrating modern analytical techniques [52].

Challenges in Harmonization

Differences in regulatory requirements and enforcement levels between countries create challenges for harmonizing

standards and complicate international trade in herbal products.

Regulatory Disparities and Harmonization Challenges

The global regulatory landscape for herbal medicines is characterized by significant disparities in requirements, enforcement mechanisms, and philosophical foundations. These differences pose major challenges to the harmonization of standards and the international acceptance of herbal products.

For instance, the European Medicines Agency (EMA) emphasizes historical use and bibliographic evidence under the Traditional Herbal Medicinal Products Directive (THMPD), while the U.S. Food and Drug Administration (FDA) regulates herbal products primarily as dietary supplements under the DSHEA, focusing on Good Manufacturing Practices but not requiring efficacy proof prior to marketing [51,53].

In contrast, China integrates traditional use with modern analytical rigor, incorporating DNA barcoding and metabolomic profiling into official pharmacopoeial monographs [25]. This has led to a more robust internal system, but challenges remain when aligning with external markets.

For countries in Africa, the Middle East, and Southeast Asia, the situation is more fragmented. Some nations lack comprehensive herbal regulatory frameworks altogether, while others partially adopt WHO guidelines without local adaptation. This mismatch creates barriers to international trade and hinders investment in quality infrastructure [2].

Harmonization efforts such as ICH-GCP, WHO Benchmarks, and regional initiatives (e.g., the African Medicines Agency) are still in early stages and require stronger political will and technical support. Tailoring harmonized standards to local realities—such as cultural practices, resource availability, and indigenous knowledge—is essential to achieving global quality assurance without marginalizing traditional systems.

Examples of National Herbal Standards from Other Regions

While most standardization discussions focus on WHO, EMA, FDA, and Chinese pharmacopoeias, several other countries have developed distinct regulatory frameworks that reflect their cultural heritage, economic capacities, and public health priorities.

In Brazil, the National Health Surveillance Agency (ANVISA) maintains a well-developed framework for herbal medicines, including a Brazilian Pharmacopoeia and specific guidelines for phytotherapeutic products. Brazil also supports the cultivation and certification of native medicinal plants through state-sponsored research programs [54].

Iran has established a comprehensive Traditional Medicine Department within its Ministry of Health, which collaborates with academic institutions to publish monographs and set quality standards for Persian medicinal plants. Integration with national healthcare services has allowed for better pharmacovigilance and patient tracking [55].

In South Africa, the Medicines Control Council (MCC) has introduced a classification system for Complementary and Alternative Medicines (CAMs), including traditional African remedies. However, implementation has faced challenges due to informal market dominance and lack of enforcement capacity [56].

Malaysia operates under the National Pharmaceutical Regulatory Agency [56], which has published specific requirements for herbal products, including stability testing, labeling, and evidence of traditional use. Products are registered under a tiered risk-based system that facilitates both traditional and evidence-based claims.

These examples illustrate that standardization is not a one-size-fits-all process, and successful implementation depends on adapting regulatory systems to local contexts while aligning with international safety benchmarks.

Challenges and Future Perspectives in Standardization

Despite significant progress, several challenges remain in the standardization of medicinal plants, and addressing these is crucial for the advancement of herbal medicine.

Complexity and Variability of Plant Materials

The chemical composition of medicinal plants varies with species, geography, climate, harvest time, and processing methods, making standardization complex [22].

Lack of Comprehensive Monographs and Databases

Many medicinal plants lack detailed pharmacopoeial monographs and chemical fingerprints, limiting consistent quality control [16].

Limited Access to Advanced Analytical Technologies

In many developing countries, access to sophisticated analytical tools and trained personnel is limited, hindering effective standardization [22].

Integration of Modern Techniques

Future efforts should focus on integrating genomics, metabolomics, and chemometrics with traditional methods to enhance precision and efficiency in standardization [23].

Strengthening Regulatory Harmonization

Global harmonization of regulatory standards can facilitate international trade and promote safety and efficacy globally [31].

Conclusion

Standardization is pivotal for bridging traditional herbal medicine and modern pharmaceuticals. While challenges like phytochemical variability and regulatory fragmentation persist, advancements in analytical technologies and international cooperation offer promising solutions. Future research should focus on validating multi-marker standardization approaches and expanding access to cost-effective methods, ensuring safe, effective, and globally accepted herbal products.

However, this review primarily focuses on common analytical methods, while emerging techniques such as nano-sensors warrant deeper exploration. Additionally, the discussion of socioeconomic barriers to implementing standardization in resource-poor regions remains limited. Moving forward, research should prioritize developing cost-effective portable devices (e.g., paper-based assays) for field testing and conducting long-term clinical studies to correlate standardization levels with therapeutic outcomes.

Statements and Declarations

Funding support

This study was not funded by any organization

Competing interests

The authors declare there is no Competing interests

Authors' contributions

The Writing an original draft :Azza Dawoud; Writing review & editing: Mohammed abdalbagi, and Azza Dawoud

Acknowledgements

"The authors acknowledge all individuals and institutions who contributed indirectly to this work."

References

1. Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. *Environ Health Perspect.* 2001;109 Suppl 1:69–75.
2. World Health Organization. WHO traditional medicine strategy: 2014–2023. Geneva: WHO Press; 2013. Available from: <https://www.who.int/publications/i/item/9789241506096>
3. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. *Front Pharmacol.* 2014;4:177.
4. Kunle OF, Egharevba HO, Ahmadu PO. Standardization of herbal medicines: A review. *Int J Biodivers Conserv.* 2012;4(3):101–12.
5. Tilburt JC, Kaptchuk TJ. Herbal medicine research and global health: an ethical analysis. *Bull World Health Organ.* 2008;86(8):594–9.
6. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview. *Evid Based Complement Alternat Med.* 2005;2(4):465–73.
7. European Medicines Agency. Guideline on specifications: test procedures and acceptance criteria for herbal substances, herbal preparations and herbal medicinal products/traditional herbal medicinal products. London: EMA; 2008. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-specifications-test-procedures-acceptance-criteria-herbal-substances-herbal-preparations-herbal-medicinal-products-traditional-herbal-medicinal-products-revision-3_en.pdf
8. Gafner S, Heinrich M. Quality and safety of herbal medical products: regulation and the need for quality assurance along the value chains. *Br J Clin Pharmacol.* 2018;84(9):1880–4.
9. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 2009;6(7):e1000097.
10. Falagas ME, Pitsouni EI, Malietzis GA, Pappas G. Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. *FASEB J.* 2008;22(2):338–42.
11. Bramer WM, Rethlefsen ML, Kleijnen J, Franco OH. Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study. *Syst Rev.* 2017;6:245.
12. Mukherjee PK, Nema NK, Maity N, Sarkar BK. Quality control and standardization of herbal drugs: A review. *J Pharm Sci.* 2019;108(1):19–28.
13. World Health Organization. Quality control methods for herbal materials. Geneva: WHO; 2011. Available from: <https://www.who.int/publications/i/item/9789241500735>
14. Xie PS, Yan YZ, Lam CWK. Quantification of herbal medicines and herbal extracts using chromatographic techniques: Quality control and standardization. *J Chromatogr B.* 2006;812(1–2):3–15.
15. Chen Y, Liu H, Zhao H. Advanced chromatographic techniques for quality control of herbal medicines. *J Chromatogr A.* 2019;1603:456–70.
16. Mukherjee PK. Quality control of herbal drugs: Current status and future challenges. *Drug Dev Ind Pharm.* 2018;44(6):914–20.
17. Kumar V, Yadav AK, Mishra S. Phytochemical complexity and standardization of herbal medicines: Analytical challenges and strategies. *Phytochem Rev.* 2021;20(3):567–89.
18. Patel S, Gupta M, Singh N. Spectroscopic techniques in phytochemical analysis: A review. *Phytochem Anal.* 2021;32(3):321–35.
19. Joshi K, Chavan P, Warude D, Patwardhan B. Molecular markers in herbal drug technology. *Curr Sci.* 2004;87(2):159–65.
20. Kress WJ, Erickson DL, Jones FA. DNA barcoding and its role in herbal medicine authentication. *Trends Plant Sci.* 2015;20(5):278–84.
21. Wang J, Yu R, Zhang Y. Analytical challenges and advances in the standardization of traditional Chinese medicines. *Trends Anal Chem.* 2019;112:167–77.
22. Gafner S. Challenges in the quality control of botanical medicines. *Planta Med.* 2020;86(1–2):1–7.
23. Zhao Z, Wang X, Wang M. Application of metabolomics and chemometrics in the quality evaluation of medicinal plants. *Phytochem Rev.* 2021;20(2):435–51.
24. Zhou S, Chen S, Li W. Current approaches and perspectives on standardization of herbal drugs. *Fitoterapia.* 2020;146:104720.
25. Zhang L, Zhang Z, Zhou Y. Quality standardization of Chinese materia medica: Advances and challenges. *Chin J Nat Med.* 2018;16(12):881–90.
26. Zhao Z, Liang Z, Chan K. Quality control of herbal medicines: Challenges and solutions. *Chin Med.* 2012;7:7.
27. Chen X, Wu G, Huang M, Xie L. Regulatory frameworks and quality control strategies for herbal medicines. *Front Pharmacol.* 2021;12:630846.
28. Fan X, Xu G, Zhang A. Standardization strategies for traditional herbal medicines: A review of quality control approaches. *J Ethnopharmacol.* 2022;284:114799.
29. Xu J, Liu T, Yin Z. Herbal drug development and industrialization in the era of evidence-based medicine. *Phytomedicine.* 2019;62:152956.
30. World Health Organization. Herbal Medicine Quality and Safety: Global Market Trends and Failures. Geneva: WHO; 2022.

31. United Nations Conference on Trade and Development. The economic contribution of medicinal plants in global trade. Geneva: UNCTAD; 2019.
32. Chen Y, Zhao H, Ma L. Impact of standardization on therapeutic consistency of herbal products: a multicenter study. *J Herb Med.* 2021;10(2):67–75.
33. European Medicines Agency. Annual Pharmacovigilance Report on Herbal Medicinal Products (2010–2020). London: EMA; 2021.
34. Li S, Zhang B, Jiang D. Influence of environmental factors on phytochemical variability in medicinal plants. *Phytomedicine.* 2019;58:152862.
35. Patwardhan B, Chaturvedi S, Singh G. Regulatory challenges for herbal medicines: Global perspective and future directions. *J Ayurveda Integr Med.* 2018;9(1):1–8.
36. Wang Y, Sun J, Liu X. Analytical technologies for herbal medicine quality control: Accessibility and challenges in developing countries. *Front Pharmacol.* 2020;11:561.
37. Sritularak B, Lertcanawanichakul M, Chanakul T. Thailand's herbal pharmacopoeia: development, implementation, and impact. *Asian J Trad Med.* 2020;15(2):102–9.
38. Asare EE, Aikins AD, Boateng D. Barriers to herbal standardization in Ghana: perspectives from traditional medicine practitioners. *Afr Health Sci.* 2019;19(4):3147–56.
39. Oladele AO, Adeniran SA. The risk of inconsistency in phytomedicines: a case from Nigeria. *J Ethnopharmacol.* 2021;278:114286.
40. Belghiti A, El Abdali Y, Bekkouch O. Standardization of Moroccan medicinal plants for export: a case study of essential oils. *J Essent Oil Res.* 2020;32(1):36–42.
41. United Nations Conference on Trade and Development. The economic contribution of medicinal plants in developing countries: infrastructure, investment, and trade. Geneva: UNCTAD; 2017.
42. Singh R, Singh R, Pandey A. Macroscopic and microscopic evaluation of medicinal plants: a practical approach. *Int J Pharm Sci Rev Res.* 2020;64(2):45–50.
43. Gupta A, Sharma V. Physicochemical standardization of medicinal plants: principles and applications. *Pharmacogn Rev.* 2017;11(22):81–8.
44. Sarker SD, Nahar L. Bioassays for pharmacological activity of herbal extracts. *Methods Mol Biol.* 2018;1735:123–41.
45. Huang M, Li X, Zhou Q. AI-driven approaches in herbal quality control and phytomedicine design. *Front Pharmacol.* 2023;14:1182432.
46. Ahmed S, Musa M, Dawoud A. Nanosensor applications for herbal quality screening in field settings. *Afr J Pharm Sci.* 2022;15(1):21–9.
47. World Health Organization. Quality control methods for herbal materials. Geneva: WHO Press; 2019. Available from: <https://www.who.int/publications/i/item/9789241500739>
48. Wachtel-Galor S, Benzie IFF, editors. Herbal medicine: biomolecular and clinical aspects. 2nd ed. Boca Raton (FL): CRC Press; 2011. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK92773/>
49. Fugh-Berman A. Herb-drug interactions. *Lancet.* 2000;355(9198):134–8.
50. European Medicines Agency. Guideline on quality documentation for herbal medicinal products. London: EMA; 2016.
51. U.S. Food and Drug Administration. Dietary supplement current good manufacturing practices (CGMPs) and adverse event reporting. Silver Spring (MD): FDA; 2020. Available from: <https://www.fda.gov/food/guidance-regulation-food-and-dietary-supplements/current-good-manufacturing-practices-cgmps-food-and-dietary-supplements>
52. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China. Beijing: China Medical Science Press; 2020.
53. Rodrigues E, Carlini EA, Bastos JK. Brazilian regulations and quality control of phytotherapeutics: historical perspectives and current status. *Rev Bras Farmacogn.* 2018;28(3):322–30.
54. Amiri MS, Joharchi MR, Hamzeloo-Moghadam M. Iranian traditional medicine and the standardization of herbal products: policies and prospects. *J Integr Med.* 2019;17(6):386–92.
55. Mothibe ME, Sibanda M. Regulatory challenges of herbal medicines in Africa: the South African perspective. *J Herb Med.* 2019;15:100224.
56. National Pharmaceutical Regulatory Agency (NPRA). Guideline for registration of traditional products. Malaysia: NPRA; 2021